Stockscreener 앱 받기
44.40
0.74%
0.41
시간 외 거래:
43.61
-0.79
-1.78%
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK
Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada
Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks
RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks
Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks
Why Have Cytokinetics Stocks Plummeted? - TipRanks
Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA - TipRanks
Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA - Marketscreener.com
Cytokinetics Completes Midcycle Review with FDA for Aficamten - TipRanks
Robert I. Blum Sells 16,970 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World
B. Riley Brokers Reduce Earnings Estimates for Cytokinetics - Defense World
Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook - sharewise
Cytokinetics EVP Fady Ibraham sells $356,025 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $144,565 in stock - Investing.com
Cytokinetics CEO Robert Blum sells shares worth $737,176 - Investing.com
Cytokinetics EVP Fady Ibraham sells $356,025 in stock - Investing.com India
Cytokinetics Executives Engage in Stock Transactions - TradingView
Cytokinetics CEO Robert Blum sells shares worth $737,176 By Investing.com - Investing.com UK
Morgan Stanley raises Cytokinetics stock to Overweight, $67 target By Investing.com - Investing.com UK
What is B. Riley’s Forecast for Cytokinetics Q1 Earnings? - Defense World
Cytokinetics assumed with an Overweight at Morgan Stanley - TipRanks
Cytokinetics Positioned for Growth: Buy Rating Backed by Aficamten’s Market Potential and Upcoming PDUFA Date - TipRanks
Cytokinetics Executives Cash In: Massive Stock Sales Unveiled! - TipRanks
Insider Sell Alert: Fady Malik Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus.com
Cytokinetics EVP Callos sells $47,768 in stock - Investing.com
Cytokinetics CEO Robert Blum sells $1.08 million in stock - Investing.com
Cytokinetics EVP Callos sells $47,768 in stock By Investing.com - Investing.com South Africa
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Cytokinetics EVP sells $85,000 in stock By Investing.com - Investing.com South Africa
Cytokinetics EVP sells $85,000 in stock - Investing.com India
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus - MSN
Cytokinetics to Participate in March Investor Conferences - The Manila Times
Where Can You Hear Cytokinetics' Latest Strategy? Three Upcoming Investor Conferences Revealed - StockTitan
Cytokinetics’ (CYTK) Buy Rating Reiterated at HC Wainwright - Defense World
New York State Common Retirement Fund Boosts Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Brokers Set Expectations for Cytokinetics Q1 Earnings - Defense World
Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Impax Asset Management Group plc Acquires 50,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Posts Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Smart Money Is Betting Big In CYTK Options - Benzinga
Oppenheimer Adjusts Price Target on Cytokinetics to $96 From $98, Maintains Outperform Rating - Marketscreener.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2024 Earnings Call Transcript - Insider Monkey
Cytokinetics’ Mixed Outlook: Hold Rating Amid Execution Challenges and Modest Trial Impact - TipRanks
Principal Financial Group Inc. Sells 1,949 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses - Yahoo Finance
Cytokinetics’ Promising Pipeline and Strategic Expansion Drive Buy Rating - TipRanks
Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses By GuruFocus - Investing.com Canada
Decoding Cytokinetics Inc (CYTK): A Strategic SWOT Insight - GuruFocus.com
Cytokinetics: Q4 Earnings Snapshot - The Washington Post
Cytokinetics plans mixed shelf offering - MSN
Cytokinetics Reports 2024 Financials and Strategic Progress - TipRanks
0.49%
1.10%
자본화:
|
볼륨(24시간):